This suggested that KRAS-mutated patients may benefit from adoptive cellular immunotherapy, including tumor-infiltrating lymphocytes (TIL) therapy and chimeric antigen receptor-modified T cells (CAR-T cells) therapy. This evidence concerns the gene KRAS and neoplasm.